Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of BridgeBio Pharma Inc (NASDAQ: BBIO) closed at $74.27 in the last session, up 0.38% from day before closing price of $73.99. In other words, the price has increased by $0.38 from its previous closing price. On the day, 2.34 million shares were traded. BBIO stock price reached its highest trading level at $75.57 during the session, while it also had its lowest trading level at $72.9.
Ratios:
We take a closer look at BBIO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.76 and its Current Ratio is at 3.88.
Upgrades & Downgrades
In the most recent recommendation for this company, Morgan Stanley on January 06, 2026, initiated with a Overweight rating and assigned the stock a target price of $96.
On December 11, 2025, Bernstein started tracking the stock assigning a Outperform rating and target price of $94.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 15 ’25 when Kumar Neil sold 30,011 shares for $74.64 per share. The transaction valued at 2,239,902 led to the insider holds 228,776 shares of the business.
NEIL KUMAR bought 30,011 shares of BBIO for $2,255,327 on Dec 15 ’25. On Dec 08 ’25, another insider, Apuli Maricel, who serves as the Chief Accounting Officer of the company, sold 2,000 shares for $74.26 each. As a result, the insider received 148,520 and left with 130,297 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 14312482816 and an Enterprise Value of 15536619520. For the stock, the TTM Price-to-Sale (P/S) ratio is 40.46. Its current Enterprise Value per Revenue stands at 43.916 whereas that against EBITDA is -27.11.
Stock Price History:
The Beta on a monthly basis for BBIO is 1.13, which has changed by 1.5443604 over the last 52 weeks, in comparison to a change of 0.19182634 over the same period for the S&P500. Over the past 52 weeks, BBIO has reached a high of $78.58, while it has fallen to a 52-week low of $28.10. The 50-Day Moving Average of the stock is 5.62%, while the 200-Day Moving Average is calculated to be 47.16%.
Shares Statistics:
According to the various share statistics, BBIO traded on average about 2.26M shares per day over the past 3-months and 1772330 shares per day over the past 10 days. A total of 192.63M shares are outstanding, with a floating share count of 164.63M. Insiders hold about 14.57% of the company’s shares, while institutions hold 87.87% stake in the company. Shares short for BBIO as of 1765756800 were 18793079 with a Short Ratio of 8.32, compared to 1763078400 on 20691850. Therefore, it implies a Short% of Shares Outstanding of 18793079 and a Short% of Float of 16.280001.
Earnings Estimates
The performance of BridgeBio Pharma Inc (BBIO) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.58 and low estimates of -$0.72.
Analysts are recommending an EPS of between -$2.77 and -$3.59 for the fiscal current year, implying an average EPS of -$3.25. EPS for the following year is -$1.85, with 4.0 analysts recommending between -$1.6 and -$2.09.
Revenue Estimates
According to 17 analysts, . The current quarter’s revenue is expected to be $148.12M. It ranges from a high estimate of $217.49M to a low estimate of $125.96M. As of . The current estimate, BridgeBio Pharma Inc’s year-ago sales were $5.88MFor the next quarter, 17 analysts are estimating revenue of $167.54M. There is a high estimate of $205.1M for the next quarter, whereas the lowest estimate is $141.8M.
A total of 20 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $565.39M, while the lowest revenue estimate was $456.4M, resulting in an average revenue estimate of $496.24M. In the same quarter a year ago, actual revenue was $221.9MBased on 18 analysts’ estimates, the company’s revenue will be $889.68M in the next fiscal year. The high estimate is $1.24B and the low estimate is $723.7M.
